Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, these claims are unequivocally false and last night The Washington Post issued a correction clarifying that PhRMA did not take a position on the legislation.
Recently, PhRMA has taken a number of steps to address the opioid crisis, such as announcing its support for a 7-day script limit on opioids for acute pain and launching a new partnership with the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) to bring new non-opioid therapies to market for patients who need them.
We will continue to work with other stakeholders to fight this terrible epidemic.
Holly Campbell Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.